Acne vulgaris: A review of the pathophysiology, treatment, and recent nanotechnology based advances

• Published in: Biochemistry and biophysics reports Vol. 36; p. 101578
• Main Authors: Vasam, Mallikarjun, Korutla, Satyanarayana, Bohara, Raghvendra Ashok
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier 01.12.2023
• Subjects: Acne inflammation; Acne pathogenesis; Acne treatment; Acne vulgaris; Review; Systemic; Topical retinoids; Acne vulgaris; Topical retinoids; Acne treatment; Acne pathogenesis; Oral antibiotics; Systemic; Acne inflammation
• ISSN: 2405-5808; 2405-5808
• DOI: 10.1016/j.bbrep.2023.101578

Globally, Acne Vulgaris is a widespread, chronic inflammatory condition of the pilosebaceous follicles. Acne is not fatal, but depending on its severity, it can leave the sufferer with scars, irritation, and significant psychological effects (including depression). In the current review, we have included various factors for acne and their treatment explained. It also narrated the current medicament and the new investigation dosage forms with clinical phases information provided. Acne's pathophysiology involves four important factors: excessive sebum production, hyperkeratinization of pilosebaceous follicles, hyperproliferation of propionibacterium acnes (P. acnes), and inflammation. Identifying both inflammatory (Papule, pustule, nodule, and cyst) and non-inflammatory (black heads, white heads) acne lesions is necessary for diagnosing and treating acne vulgaris. In this review, traditional therapy approaches such as topical (i.e., retinoids and antibiotics), systemic (i.e., retinoids, antibiotics, and hormonal), and physical therapies are briefly discussed. In addition, we highlight the issues posed by P. acne's resistance to the antibiotics used in commercially available medications and the necessity for novel therapeutic techniques. Finally, we examined a few innovative acne therapies pending clinical trial approval and commercial acne medications.